D espite significant advantages in loading, targeting, and safety, among others, provided by synthetic vectors for gene delivery, they still do not compare well with viral vectors in terms of delivery efficiency. 1À5 A variety of polymeric, 6À8 liposomal, 9, 10 protein-based, 11, 12 organic, 13, 14 and inorganic 15, 16 materials have been developed to incorporate certain viral characteristics, and vector platforms which can cohesively integrate multiple functionalities present the greatest potential utility. 17 The needs in artificial virus development for DNA delivery have been outlined previously; 3 briefly, therapeutic loading, stability and longevity in vascular transit, distribution to and uptake into the cells of interest, endosomal escape, intracellular trafficking, nuclear import, and transcriptional promotion and lifespan must be rationally considered in effective vector design. The hepatocytes of the liver present as desirable gene therapy targets for a variety of disease states, 5, 18 including Wilson Disease, 19 R1-Antitrypsin Deficiency, 20 viral hepatitis, 5 and Factor VII Deficiency, 21 primarily due to systemic accessibility, the highly endocytic nature of hepatocytes, and the potential for high degrees of tissue exposure based on organ physiology. 5 The hepatic sinusoidal epithelium acts as the primary structural and functional barrier to hepatocyte exposure, with fenestrations (numbering 8.7 ( 0.5/μm 2 with an average diameter of 141 ( 10.8 nm in C57BL/6 mice) patrolled by a large population of resident immune cells (e.g., Kupffer cells). 22, 23 Typically, formulations employ a dense coating of antifouling agents such as polyethylene glycol (PEG) to both increase circulation longevity and limit alternative cell uptake, as well as active targeting strategies to promote uptake by hepatocytes; sugars such as galactose 24, 25 and N-acetylgalactosamine 8 have been studied extensively in this regard for uptake via the asialoglycoprotein receptor (ASGPR). Upon internalization into endosomes, the contents of the delivery vehicle must escape to avoid lysosomal sequestration, a process typically achieved by buffering-induced osmotic bursting, 26 cationic lipid-mediated ion-pair formation, 27 or various other endosomolytic molecules. 10, 28 After release, however, trafficking to the nucleus and nuclear import must still be mediated. Interest has been shown in a variety of oligopeptide species employing high densities of cationic charge (lysine, 29 arginine, 30, 31 and histidine 32 residues), either alone or in concert with nuclear localization sequences, to support nuclear translocation; specifically, arginine-rich bioreducible polymers and polypeptides have been explored in vitro 29, 30 and in vivo 17, 33 as efficacious and nontoxic transfection systems. However, extensive vesicular entrapment of arginine-rich materials has been suggested as the primary inefficiency of their use in DNA delivery. 34 With such studies in mind, we have developed membrane-core nanoparticles (LCP, Liposome Calcium Phosphate) inspired by rational design, integrating calcium phosphate nanoprecipitate (CaP) cores, cysteine-flanked octaarginine peptides (Cys-(Arg) 8 -Cys, CR8C; Supporting Information Figure s1 ), and asymmetric lipid membranes 35 (densely coated with PEG and targeted via galactose ligands) together to achieve surprising levels of gene expression within hepatocytes in vivo through intravenous injection in a nonhydrodynamic manner. Targeted LCP distributed rapidly and extensively to the liver and was predominantly internalized by hepatocytes, while the inclusion of such peptides in LCP was sufficient to promote high degrees of nuclear translocation and expression of plasmid DNA. Interestingly, co-delivery with monocyclic CR8C significantly enhanced in vivo gene expression over 10-fold more than linear CR8C, possibly due to differences in the degree of peptide-DNA In.
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condensation and dissociation upon release. Based on our exploration of the current literature, our formulation presents as the most effective synthetic vector for liver gene transfer.
RESULTS AND DISCUSSION
Representative multifunctional features of the membrane-core LCP structures are shown in Figure 1a . A reverse microemulsion established by a strong surfactant (IGEPAL-520) is utilized to prepare small, 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA)-coated CaP nanoparticles (LCP "cores") which can encapsulate both DNA (appx. 50% efficiency) and peptides, with core size ranging from 20 to 30 nm in diameter. 35 The hollow core structure can be visualized under Transmission Electron Microscopy (TEM) (Figure 1b) . Further, the DOPA monolayer surrounding the CaP core allows for the confined assembly of outer leaflet lipids
, producing sub-100 nm particles ("final" LCP, 40À60 nm in diameter, shown in Figure 1c ) which can easily penetrate hepatic sinusoidal fenestrations.
PEGylation of LCP was confirmed by a fluorescence method, in separation from micelles via sucrose gradient centrifugation, to be 20 mol % of outer leaflet lipids (data not shown). The hydrodynamic diameter and the surface charge of the LCP particles are outlined in Table 1 . Dynamic light scattering indicated that LCP was narrowly dispersed around 55 nm in diameter, with a near-neutral zeta potential (around þ9 mV) due to charge shielding by PEGylation. LCP was radiolabeled with 111 In during the preparation of CaP core in a similar manner to previously published methods 36 and intravenously injected into C57BL/6 female mice to examine its distribution in vivo.
Quantitative pharmacokinetic and biodistribution analyses of 111 In-labeled LCP indicated that galactosetargeted LCP distributed rapidly and primarily to the liver ( Figure 2 and Such a perspective is supported by the increased (3-fold) degree of liver distribution, decreased (4-fold) distribution half-life, and increased in vitro hepatocyte uptake (Table 2 ) associated with the galactosylated particles.
The synergistic function of the cationic lipids and the acid-sensitive CaP in the lysis of the endosome has been described previously for LCP, 35 however, effective nuclear import still presents as a significant challenge toward establishing efficacy, especially in nonproliferative cells such as hepatocytes. Viral vectors ARTICLE typically employ nuclear localization sequences (NLS) for translocation of genetic material, which are readily recognized by the cellular nuclear transport machinery. 38 In terms of cellular uptake, octaarginine mimics the NLS of the HIV-1 Tat protein (Tat-(48À60)); 10,39À41 however, on a postendosomal basis, its utility has not been fully characterized. In order to examine their effects on the intracellular distribution of the delivered DNA in the liver, Cy3-labeled DNA was encapsulated in different formulations of LCP (with linear CR8C (l-CR8C), with monocyclic CR8C (mc-CR8C), or without CR8C) and intravenously injected into C57BL/6 female mice. Livers were harvested 6 h postadministration, and their cryo-sections were observed by confocal microscopy after staining actin and nuclei. LCP encapsulating no CR8C was taken up into most of the hepatocytes in the liver; however, the majority of the Cy3-DNA distributed homogeneously in the cytoplasm (Figure 3 ). Co-encapsulation with either mc-CR8C or l-CR8C elicited extensive Cy3-DNA distribution to the hepatocyte nuclei, strongly suggesting that the arginine-rich peptides could mediate delivery of DNA into the nucleus. In vitro study further supported the efficient nuclear delivery of Cy3-DNA by coencapsulation with such peptides in LCP, with more than 90% of nuclei presenting strong Cy3 fluorescence (Supporting Information Figure s3 ). Such extensive uptake into hepatocytes in vivo is likely supported in part by effective mononuclear phagocyte evasion as well; our lab has recently shown extensive evasion of Kupffer cell uptake by LCP at higher densities of outer leaflet lipid PEGylation (greater than 10À15 mol %). 42 The most powerful nonviral method, hydrodynamic (HD) injection, 43 was used as a positive control to deliver Cy3-DNA to the liver. Fluorescence was observed in this case to be punctate and largely confined to the cytoplasm, with a minor amount accumulating in hepatocyte nuclei. Plasmids encoding tdTomato red fluorescence protein (RFP) or firefly luciferase (Luc) driven by the cytomegalovirus promoter were then used, respectively, as semi-quantitative and quantitative reporter genes by which to characterize LCP as a vector in mice. Expression and activity were evaluated at 24 h postinjection, and analysis of major organs confirmed predominant hepatic transgene expression (Figure 4 ). RLU/mg protein at a 0.3 mg DNA/kg dose) in the liver over l-CR8C. Since the two peptides were not observably different in supporting the nuclear import of plasmid DNA (Figure 3 ), such differences in reporter gene expression may involve differences in peptidemediated plasmid condensation and release. It has been reported that excessive strength in DNA complexation by peptide-based condensing agents can both limit intracellular release and reduce overall efficacy, 44 often on structural and sequence-specific bases. 45 Likely supported by a greater conformational flexibility, l-CR8C more readily condensed plasmid DNA than mc-CR8C, as shown by an enhanced ability to exclude DNA-SYBR Green fluorescence (Figure 5a ) and a more limited dissociation profile in the presence of anionic materials such as hyaluronan (Figure 5b) . Further, the uneven fluorescence distribution in the nuclei (Figure 3) suggests that the DNA was still bound in rigid complexes, which could hinder DNA trafficking and transcription within the nuclei. Our HD comparator supports such a perspective as well; although HD injection delivers less DNA overall to the nuclei (Figure 3) , all of such DNA would be free for transcription. Notably, our results present a step toward the outperformance of HD injection; though 100-fold lower in gene expression, our system presents a greatly decreased invasiveness in its application.
Our gene delivery system compares favorably against a variety of synthetic vectors on the basis of luciferase activity in vivo. For example, intratumoral injection of poly(amine-co-ester)-DNA complexes (0.5 mg DNA/kg) at best elicited luciferase activity on the order of 10 5 RLU/mg protein despite a simplified delivery process. 46 Hepatic luciferase activity of 7.5 Â 10 5 RLU/mg protein was observed after intravenous administration of a galactose-conjugated bifunctional dendrimer (2.5 mg DNA/kg). 47 The optimal linear, cationic polymer from a small azideÀalkyne click library supported gene expression in a subcutaneous tumor relative to 10 6 RLU/mg protein when dosing intravenously at 2 mg DNA/kg. 48 Alkylated (ethyl) polyethyleneimine (PEI) produced similar results as well in intravenous delivery to the lungs (2.5 mg DNA/kg). 49 One of the best direct comparisons, however, can be made to the pH-sensitive and octaarginine-modified 35 The high intracellular calcium conditions produced by our formulation may aid in endosomal release as well. 50 Further, establishing the octaarginine peptide within the nanoparticle core may better promote DNA delivery on a post-endosomal basis. Systemic toxicity and cytokine induction of LCP was investigated 24 h after intravenous administration to C57BL/6 mice as well. There were no obvious histological differences between the major organs of treated and untreated mice (Figure 6 ), and hematological markers remained relatively unperturbed; however, a notable increase in TNF-R was observed (Table 3) . Further analysis will be required to determine the significance, if any, of such a response.
CONCLUSIONS
We have developed membrane-core LCP nanoparticles that address a variety of the needs in DNA delivery, integrating together DOPA-coated CaP cores, octaarginine peptides, cationic and PEGylated lipids, and galactose targeting ligands to achieve high levels of gene expression in vivo (Scheme 1). The strength and stability of such cores under physiological conditions confer the desired protection against degradation in circulation while supporting both an asymmetric and a highly functionalized lipid bilayer. Such a formulation can efficiently encapsulate DNA as a relatively small vector which presents as ideal in size and PEGylation for delivery to hepatocytes in vivo. Further, ASGPR-targeting via galactose supports increased and rapid distribution to the liver, presumably through an increased rate of internalization of LCP. Such particles have shown to be effective in cytosolic release of DNA, and co-delivery with the cationic peptides CR8C supports extensive nuclear translocation in post-mitotic cells, with favorable release from mc-CR8C likely contributing to enhanced efficacy over l-CR8C. Gene expression still limits nonviral efforts, 51 as can be observed by comparison to hydrodynamic injection; however, this formulation presents as a much less invasive alternative and, to our knowledge, it is the most effective synthetic vector for liver gene transfer. Six-week-old C57BL/6 female mice (∼18 g each) were purchased from Charles River Laboratories (Wilmington, MA). All work performed on animals was in accordance with and approved by the University of North Carolina Institutional Animal Care and Use Committee.
MATERIALS AND METHODS
Methods. Preparation and Characterization of LCP Loaded with DNA. LCP was prepared using a modified protocol. 35 Two separate microemulsions (20 mL each) were prepared of Igepal 520 and cyclohexane (3:7 v/v) and placed under stirring. DNA (60 μg) was added to 600 μL of 2.5 M CaCl 2 , whose pH had been titrated above 7 with NaOH. To this solution, octaarginine peptides were added at an N:P ratio of 2:1. A Na 2 HPO 4 solution (600 μL, 12.5 mM, pH 9) was also prepared, as was 250 μL of . To one emulsion, the calcium phase was added, while to the other, both the phosphate solution and DOPA were added; both emulsions were left to stir for 20 min. The emulsions were then mixed, and left to stir an additional 20 min. An equal volume of 100% EtOH was added to disrupt the emulsion, and the mixture was centrifuged at 10 000g for 20 min. After decanting the supernatant, the precipitate was washed twice thereafter with 100% EtOH to remove traces of Igepal and/or cyclohexane. The precipitate was then dried under N 2 , and resuspended in CHCl 3 . This solution was centrifuged at 6000 rpm for 5 min for the removal of large aggregates, and the supernatant containing the LCP "cores" (DNA and peptide entrapped within a calcium phosphate nanoprecipitate, supporting and surrounded by a lipid monolayer of DOPA) was recovered.
To characterize DNA entrapment efficiency, firefly luciferase cDNA was labeled with Cy3 (Mirus LabelIT kit, Mirus Bio, Madison, WI) according to manufacturer instructions. Such Cy3-DNA was formulated into the LCP cores, after which recovery was assessed via fluorescence spectrometry.
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Inlabeled LCP cores were prepared as described previously, In. LCP was produced through desiccation of a mixture of free lipids and cores (2.5:1 ratio of total free lipids to DOPA) and subsequent rehydration. Therein, 35 mol % DOTAP, 35 mol % cholesterol, and 30 mol % DSPE-PEG 2000 (or 25 mol % DSPE-PEG and 5 mol % DSPE-PEG-Gal) were utilized as outer leaflet lipids. Zeta potential and particle size of LCP were measured using a Malvern ZetaSizer Nano Series (Westborough, MA). TEM images of LCP were acquired using a JEOL 100CX II TEM (JEOL, Japan).
Pharmacokinetics, Biodistribution, and Intracellular Distribution of Cy3-DNA Delivered by LCP. LCP containing Cy3-DNA, both untargeted and targeted via galactose ligands (LCP-PEG and LCP-Gal, respectively, 0.2 mg/kg DNA dose), were injected (0.2 mL, balanced in osmolarity with the addition of dextrose) into 6-week-old C57/BL female mice through the tail vein. Liver tissues were frozen in OCT compound for sectioning. Liver sections (10 μm) were fixed with cold acetone, washed in PBS, and incubated for 5 min with fluorescein isothiocyanate (FITC)-labeled phalloidin in PBS. The sections were stained with DAPI prior to mounting with Fluor-mount G (Southern Biotech), and imaged on a Leica SP2 confocal microscope. UV, Cy3, and FITC filters were set up to image nuclei, intracellular DNA distribution, and actin, respectively.
Pharmacokinetics and quantitative biodistribution were further determined via coencapsulation with 111 In (incorporated into the calcium emulsion during formulation) in the nanoprecipitate. Such methods have been utilized previously to accurately determine LCP biodistribution. 36 Six-week-old C57BL/6 female mice (6 mice utilized for each group) were injected individually (0.2 mL, balanced in osmolarity with the addition of dextrose) with LCP at 0.1 mg DNA/kg, corresponding to a dose of 8 Â 10 6 cpm/kg of 111
In. For pharmacokinetic analysis, blood was recovered at various time points (20, 90, 200, 390, 480 , 600, and 720 min) via retro-orbital bleed. For biodistribution analysis, 6 and 12 h after the administration of LCP, the blood and major organs were collected (6 mice utilized for each time point). Radioactivity in the blood and tissues in both studies was measured using a γ-counter. Analysis was conducted under a two-compartment model utilizing Phoenix WinNonlin (Version 6.3, Pharsight Corporation; Mountain View, CA).
In Vivo Gene Expression. Several groups of LCPs containing cDNA encoding tdTomato red fluorescence protein (RFP) or firefly luciferase (Luc) were injected (0.2 mL, balanced in osmolarity with the addition of dextrose) into 6-week-old C57BL/6 female mice (0.3 mg DNA/kg, 3 mice utilized for each group) through the tail vein. Hydrodynamic injection was conducted by rapid injection of a 1.6 mL solution of equal DNA dose in PBS. The major organs of the RFP-transfected mice were harvested 24 h postinjection and visualized using a Kodak in vivo imaging system FX Pro (Kodak, Rochester, NY) at ex/em = 550/600 nm. For quantitative analysis of gene expression via luciferase activity, lysis buffer (0.1 M Tris-HCl, 2 mm EDTA, 0.1% Triton X-100, pH 7.8) was added to each whole organ (1 mL per kidney, spleen, lung, or heart; 15 mL per liver). Each organ was homogenized for 30 s, and homogenates were then centrifuged at 4°C for 10 min at 13 000g. Total protein concentration in the lysate was determined through a bicinchoninic acid protein assay kit (BCA Protein Assay Kit, Pierce, Rockford, IL). Ten microliters of each homogenate supernatant was mixed with 90 μL of luciferase assay reagent (Luciferase Assay System, Promega Co., Madison, WI) and the luminescence intensity was measured via plate reader (Bioscan, Inc., Washington, DC) for 1 s. The activity of luciferase is shown as the luminescence intensity per milligram of protein.
DNA Condensation and Release from CR8C. DNA condensation refers to an inhibition of the DNA-intercalated SYBR green fluorescence signal in the presence of either l-CR8C or mc-CR8C peptides. The assay was carried out in 1.5 mL Eppendorf tubes, where 10 μL of SYBR Green (10 000 dilution from stock) and 10 μL of pDNA (100 ng/μL) in 1 mL of 100 mM Tris-HCl (pH 8.0) were mixed and incubated in the dark for 5 min at room temperature. Twenty microliters of peptide solutions corresponding to different charge ratios was subsequently added, followed by incubation in the dark for 15 min. Two controls were prepared without peptide added. Fluorescence signals were recorded at a 497/520 excitation/emission (fluorescence spectrometer, Perkin-Elmer, Waltham, MA), with the control values taken as maximum (i.e., 100%). The inhibition in fluorescence signal was calculated at increasing charge ratios and plotted as percentage of maximum.
For DNA release, the DNAÀpeptide complexes (10 μL of 100 ng/μL pDNA in each case) were prepared at a charge ratio 4 and incubated with 10 μL of SYBR Green (10 000 dilution from stock) in 1 mL of 100 mM Tris-HCl buffer (pH 8.0) for 30 min at room temperature. Thirty microliters of hyaluronic acid solution was added to the different tubes of DNAÀ-peptide complexes with SYBR green at increasing amounts. Three controls (pDNA with SYBR green, SYBR green alone, and hyaluronic acid with SYBR green) were also prepared. The fluorescence was recorded as described in the condensation section. The fluorescence value of pDNAÀpeptide complexes without any hyaluronic acid was taken as 100%, and the relative percentage increase in fluorescence signal was calculated at increasing concentration of hyaluronic acid solutions in terms of charge ratio over the negative charges of DNA.
Toxicity and Pathology Studies. Twenty-four hours after mice were treated with luciferase DNA and mc-CR8C-loaded LCP (0.4 mg DNA/kg) (three mice utilized for each group), serum was obtained from the mice via retro-orbital bleed and centrifugation. Hepatic and renal damage was assessed by measuring the levels of AST, ALT and BUN in the serum samples. These measurements were quantified by the Animal Clinical Chemistry and Gene Expression Laboratories at UNC Chapel Hill. An ELISA assay kit (BD Biosciences, San Diego, CA) was used to perform a cytokine induction assay, providing the IL-6, IL-12, IFN-γ and TNF-R levels in the mouse serum. Further, the major organs of each mouse were collected, fixed, and processed thereafter for H&E staining. Images of tissue sections were collected using a Nikon light microscope with 10Â objective. The 95% CI were derived from the technical data sheet C57BL/6 Mouse Hematology (North American Colonies, January 2008 to December 2011), Charles River Laboratories (Wilmington, MA).
Statistical Analysis. Statistical analysis in luciferase activity comparisons was conducted using Bonferroni-corrected t tests. A p < 0.0125 was considered significant.
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